

I, Judith Atkinson, BA.(Hons.), MITI., translator to Messrs. Taylor and Meyer of 20 Kingsmead Road, London, SW2 3JD, Great Britain, verify that I know well both the German and the English language, that I have prepared the attached English translation of 34 pages of a German Patent application in the German language with the title:

Neue für das luxR-Gen kodierende Nukleotidsequenzen

identified by the code number 000177 BT at the upper left of each page and corresponding to client/matter number of the law firm of

and that the attached English translation of this document is a true and correct translation of the document attached thereto to the best of my knowledge and belief.

I further declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that wilful false statements and the like are punishable by fine or imprisonment, or both, under 18 USC 1001, and that such false statements may jeopardize the validity of this document.

Date: 20th March 2003

By: J.M. Attison

# FEDERAL REPUBLIC OF GERMANY

# Certificate of Priority for Filing of a Patent Application

Filing number:

100 39 043.9

Filing date:

10th August 2000

Applicant/Proprietor:

Degussa AG, Düsseldorf/Germany
<u>First applicant:</u> Degussa-Hüls
Aktiengesellschaft, Frankfurt am

Main/Germany

Title:

Novel nucleotude sequences coding for

the luxR gene

IPC:

C 07 H, C 12 P, C 12 N

The attached papers are a true and accurate reproduction of the original documents for this patent application.

Munich, 13th June 2001

On behalf of the President of the German Patent and Trade Mark Office

(signature)
Faust

000177 BT

# Novel nucleotide sequences coding for the luxR gene

The invention provides nucleotide sequences from coryneform bacteria coding for the luxR gene, and a process for the production, by fermentation, of amino acids, particularly 5 L-lysine, by attenuating the luxR gene. The luxR gene codes for the LuxR protein, which is a transcription activator.

## Prior art

L-amino acids, particularly L-lysine, are used in human medicine and in the pharmaceuticals industry, in the food10 stuffs industry and, most particularly, in the feeding of animals.

It is known that amino acids are produced by fermentation of strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great

- 15 importance, attempts are continuously being made to improve the production processes. Improvements to the processes may concern measures relating to the fermentation, such as, for example, stirring and oxygen supply, or the composition of the nutrient media, such as, for example, the sugar
- 20 concentration during the fermentation, or working up to the product form by, for example, ion-exchange chromatography, or the intrinsic performance properties of the microorganism itself.
- In order to improve the performance properties of such microorganisms, methods of mutagenesis, selection and mutant selection are employed. Such methods yield strains which are resistant to antimetabolites or are auxotrophic for metabolites that are important in terms of regulation, and which produce amino acids.
- 30 For a number of years, methods of recombinant DNA technology have also been used for improving the strain of L-amino acid-producing strains of Corynebacterium.

Object of the invention

The inventors have set themselves the object of providing novel measures for the improved production of amino acids, in particular L-lysine, by fermentation.

5 Description of the invention

The invention provides an isolated polynucleotide from coryneform bacteria, containing a polynucleotide sequence coding for the luxR gene, selected from the group

- a) polynucleotide that is at least 70% identical with a
   polynucleotide that codes for a polypeptide containing the amino acid sequence of SEQ ID No. 2,
  - b) polynucleotide that codes for a polypeptide containing an amino acid sequence that is at least 70% identical with the amino acid sequence of SEQ ID No. 2,
- 15 c) polynucleotide that is complementary to the polynucleotide of a) or b), and
  - d) polynucleotide containing at least 15 consecutive nucleotides of the polynucleotide sequence of a), b) or c),
- 20 the polypeptide preferably exhibiting the activity of the transcription activator LuxR.

The invention also provides the above-mentioned polynucleotide, it preferably being a replicatable DNA containing:

- 25 (i) the nucleotide sequence shown in SEQ ID No. 1, or
  - (ii) at least one sequence that corresponds to sequence (i) within the region of the degeneracy of the genetic code, or

- (iii) at least one sequence that hybridizes with the sequences that are complementary to sequence (i) or (ii), and optionally
- (iv) sense mutations in (i) that are neutral in terms of 5 function.

The invention also provides:

- a replicatable DNA containing the nucleotide sequence as shown in SEQ ID No. 1;
- a polynucleotide that codes for a polypeptide containing the amino acid sequence as shown in SEQ ID No. 2;
  - a vector containing the polynucleotide accoording to the invention, point d, particularly pCR2.1luxRint, deposited in Escherichia coli DSM 13619 at the DSMZ, Braunschweig (Germany);
- 15 and coryneform bacteria that contain in the luxR gene an insertion or deletion, particularly using the vector pCR2.lluxRint.

The invention also provides polynucleotides consisting substantially of a polynucleotide sequence, which are 20 obtainable by screening, by means of hybridization, a corresponding gene library that contains the complete gene having the polynucleotide sequence according to SEQ ID No. 1, using a probe containing the sequence of the mentioned polynucleotide according to SEQ ID No. 1 or a 25 fragment thereof, and isolating the mentioned DNA sequence.

Polynucleotide sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate in their complete length nucleic acids or polynucleotides or genes that code for the LuxR protein, or 30 in order to isolate nucleic acids or polynucleotides or

genes that have a high degree of similarity with the sequence of the luxR gene.

Polynucleotide sequences according to the invention are also suitable as primers, with the aid of which it is 5 possible, by means of the polymerase chain reaction (PCR), to produce DNA of genes that code for the LuxR protein.

Such oligonucleotides acting as probes or primers contain at least 30, preferably at least 20, very particularly preferably at least 15, consecutive nucleotides. Also suitable are oligonucleotides having a length of at least 40 or 50 nucleotides.

"Isolated" means removed from its natural environment.

"Polynucleotide" generally refers to polyribonucleotides and polydeoxyribonucleotides, it being possible for the RNA or DNA to be unmodified or modified.

"Polypeptides" are to be understood as being peptides or proteins that contain two or more amino acids bonded *via* peptide bonds.

The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, particularly those having the biological activity of the LuxR protein, and also those that are at least 70%, preferably at least 80% and in particular at least from 90% to 95% identical with the polypeptide according to SEQ ID No. 2, and exhibit the 25 mentioned activity.

The invention also provides a process for the production of amino acids, particularly L-lysine, by fermentation using coryneform bacteria which, in particular, already produce amino acids and in which the nucleotide sequences coding for the luxR gene are attenuated, in particular excluded or expressed at a low level.

The term "attenuation" in this connection describes the diminution or exclusion of the intracellular activity of one or more enzymes (proteins) in a microorganism that are coded for by the corresponding DNA, by, for example, using a weak promoter or using a gene or allele that codes for a corresponding enzyme having low activity, or by inactivating the corresponding gene or enzyme (protein), and optionally by combining those measures.

The microorganisms provided by the present invention are
10 able to produce amino acids, in particular L-lysine, from
glucose, saccharose, lactose, fructose, maltose, molasses,
starch, cellulose or from glycerol and ethanol. They may be
representatives of coryneform bacteria, particularly of the
genus Corynebacterium. In the case of the genus

15 Corynebacterium, special mention may be made of the species Corynebacterium glutamicum, which is known to those skilled in the art for its ability to produce L-amino acids.

Suitable strains of the genus Corynebacterium, particularly of the species Corynebacterium glutamicum (C. glutamicum), 20 are in particular the known wild-type strains

Corynebacterium glutamicum ATCC13032
Corynebacterium acetoglutamicum ATCC15806
Corynebacterium acetoacidophilum ATCC13870
Corynebacterium melassecola ATCC17965
Corynebacterium thermoaminogenes FERM BP-1539
Brevibacterium flavum ATCC14067
Brevibacterium lactofermentum ATCC13869 and
Brevibacterium divaricatum ATCC14020

or L-amino acid-producing mutants or strains prepared
30 therefrom, such as, for example, the L-lysine-producing
strains

Corynebacterium glutamicum FERM-P 1709 Brevibacterium flavum FERM-P 1708 Brevibacterium lactofermentum FERM-P 1712
Corynebacterium glutamicum FERM-P 6463
Corynebacterium glutamicum FERM-P 6464
Corynebacterium glutamicum DM58-1
Corynebacterium glutamicum DG52-5
Corynebacterium glutamicum DSM 5714 and
Corynebacterium glutamicum DSM 12866.

The inventors have succeeded in isolating the new luxR gene of C. glutamicum that codes for the LuxR protein, which 10 gene is a transcription activator.

In order to isolate the luxR gene or also other genes of C. glutamicum, a gene library of that microorganism in Escherichia coli (E. coli) is first prepared. The preparation of gene libraries is written down in generally 15 known textbooks and handbooks. There may be mentioned as an example the textbook of Winnacker: Gene und Klone, Eine Einführung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990) or the handbook of Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor 20 Laboratory Press, 1989). A very well known gene library is that of the E. coli K-12 strain W3110, which has been prepared by Kohara et al. (Cell 50, 495-508 (1987)) in  $\lambda$ vectors. Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum 25 ATCC13032, which has been prepared with the aid of the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in the E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575). Bormann et al. (Molecular

30 Microbiology 6(3), 317-326 (1992)) in turn describe a gene library of C. glutamicum ATCC13032 using the cosmid pHC79 (Hohn and Collins, 1980, Gene 11, 291-298).

For the preparation of a gene library of C. glutamicum in E. coli it is also possible to use plasmids such as pBR322 35 (Bolivar, 1979, Life Sciences, 25, 807-818) or pUC9 (Vieira

et al., 1982, Gene, 19:259-268). Suitable hosts are particularly those E. coli strains that are restriction—and recombination—defective, such as, for example, the strain DH5α (Jeffrey H. Miller: "A Short Course in
Bacterial Genetics, A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria", Cold Spring Harbour [sic] Laboratory Press, 1992).

The long DNA fragments cloned with the aid of cosmids or other  $\lambda$ -vectors can then in turn be subcloned into 10 customary vectors suitable for DNA sequencing.

Methods of DNA sequencing are described *inter alia* in Sanger *et al.* (Proceedings of the National Academy of Sciences of the United States of America USA, 74:5463-5467, 1977).

15 The resulting DNA sequences can then be studied using known algorithms or sequence-analysis programs, such as, for example, that of Staden (Nucleic Acids Research 14, 217-232 (1986)), that of Marck (Nucleic Acids Research 16, 1829-1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)).

In that manner, the novel DNA sequence of C. glutamicum coding for the luxR gene has been obtained, which sequence, as SEQ ID No. 1, forms part of the present invention. Furthermore, the amino acid sequence of the corresponding

25 protein has been derived from the present DNA sequence using the methods described above. The resulting amino acid sequence of the luxR gene product is shown in SEQ ID No. 2.

Coding DNA sequences that result from SEQ ID No. 1 by the degeneracy of the genetic code also form part of the

30 invention. Likewise, DNA sequences that hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 form part of the invention. Furthermore, to those skilled in the art, conservative amino acid substitutions, such as, for

example, the substitution of glycine with alanine or of aspartic acid with glutamic acid, in proteins are known as sense mutations, which do not lead to any fundamental change in the activity of the protein, that is to say are 5 neutral in terms of function. It is also known that changes at the N- and/or C-terminus of a protein do not substantially impair its function or may even stabilise it. The person skilled in the art will find relevant information inter alia in Ben-Bassat et al. (Journal of 10 Bacteriology 169:751-757 (1987)), in O'Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences that result in a 15 corresponding manner from SEQ ID No. 2 likewise form part of the invention.

Finally, DNA sequences that are produced by the polymerase chain reaction (PCR) using primers that result from SEQ ID No. 1 form part of the invention. Such oligonucleotides 20 typically have a length of at least 15 nucleotides.

The person skilled in the art will find instructions on the identification of DNA sequences by means of hybridization inter alia in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH

- 25 (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology 41: 255-260 (1991)). The person skilled in the art will find instructions on the amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) inter alia in the hand-
- 30 book of Gait: Oligonukleotide [sic] Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

During work on the present invention it has been found that 35 coryneform bacteria produce amino acids, in particular

L-lysine, in an improved manner after attenuation of the luxR gene.

In order to achieve attenuation, either the expression of the luxR gene or the catalytic properties of the enzyme 5 protein can be diminished or excluded. The two measures may optionally be combined.

A diminution of gene expression can be effected by carrying out the culturing in a suitable manner or by genetic alteration (mutation) of the signal structures of gene

- 10 expression. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome-binding sites, the start codon and terminators. The person skilled in the art will find information thereon, for example, in patent
- 15 application WO 96/15246, in Boyd and Murphy (Journal of Bacteriology 170: 5949 (1988)), in Voskuil and Chambliss (Nucleic Acids Research 26: 3548 (1998), in Jensen and Hammer (Biotechnology and Bioengineering 58: 191 (1998)), in Pátek et al. (Microbiology 142: 1297 (1996)), Vasicova
- 20 et al. (Journal of Bacteriology 181: 6188 (1999)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of Knippers ("Molekulare Genetik", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that of Winnacker ("Gene und Klone", VCH
- 25 Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations that lead to a change in or diminution of the catalytic properties of enzyme proteins are known from the prior art; examples which may be mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272:

- 30 8611-8617 (1997)), Sugimoto et al. (Bioscience Biotechnology and Biochemistry 61: 1760-1762 (1997)) and Möckel ("Die Threonindehydratase aus Corynebacterium glutamicum: Aufhebung der allosterischen Regulation und Struktur des Enzyms", Reports from the Jülich Research
- 35 Centre, Jül-2906, ISSN09442952, Jülich, Germany 1994).

Summaries are to be found in known textbooks of genetics and molecular biology, such as, for example, that of Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

- 5 There come into consideration as mutations transitions, transversions, insertions and deletions. In dependence on the effect of the amino acid substitution on the enzyme activity, missense mutations or nonsense mutations are referred to. Insertions or deletions of at least one base
- 10 pair (bp) in a gene lead to frame shift mutations, as a result of which incorrect amino acids are incorporated or the translation breaks off prematurely. Deletions of several codons typically result in a complete loss of enzyme activity. Instructions for the production of such
- 15 mutations are part of the prior art and are to be found in known textbooks of genetics and molecular biology, such as, for example, the textbook of Knippers ("Molekulare Genetik", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that of Winnacker ("Gene und Klone", VCH
- 20 Verlagsgesellschaft, Weinheim, Germany, 1990) or that of Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

A common method of mutating genes of C. glutamicum is the method of gene disruption and of gene replacement described by Schwarzer and Pühler (Bio/Technology 9, 84-87 (1991)).

In the method of gene disruption, a central portion of the coding region of the gene in question is cloned into a plasmid vector which is able to replicate in a host (typically E. coli), but not in C. glutamicum. Suitable

- 30 vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pK18mobsacB or pK19mobsacB (Jäger et al., Journal of Bacteriology 174: 5462-5465 (1992)), pGEM-T (Promega corporation, Madison,
- 35 WI, USA), pCR2.1-TOPO (Shuman (1994). Journal of Biological

Chemistry 269:32678-32684; US Patent 5,487,993), pCR®Blunt (Invitrogen, Groningen, Netherlands; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)) or pEM1 (Schrumpf et al., 1991, Journal of Bacteriology 173:4510-

- 5 4516). The plasmid vector containing the central portion of the coding region of the gene is then transferred to the desired strain of C. glutamicum by conjugation or transformation. The method of conjugation is described, for example, in Schäfer et al. (Applied and Environmental
- 10 Microbiology 60, 756-759 (1994)). Methods of transformation are described, for example, in Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)).
- 15 After homologous recombination by means of a cross-over occurrence, the coding region of the gene in question is disrupted by the vector sequence, and two incomplete alleles lacking the 3'- and the 5'-end, respectively, are obtained. That method has been used, for example, by
- 20 Fitzpatrick et al. (Applied Microbiology and Biotechnology 42, 575-580 (1994)) to exclude the recA gene of C. glutamicum.

Figure 1 shows by way of example the plasmid vector pCR2.1luxRint, by means of which the luxR gene can be disrupted or excluded.

In the gene replacement method, a mutation, such as, for example, a deletion, insertion or base substitution, is produced *in vitro* in the gene in question. The allele that is produced is in turn cloned into a vector that is not

- 30 replicative for C. glutamicum, and the latter is then transferred to the desired host of C. glutamicum by transformation or conjugation. After homologous recombination by means of a first cross-over occurrence effecting integration and by means of a suitable second
- 35 cross-over occurrence effecting an excision in the target

gene or in the target sequence, incorporation of the mutation or of the allele is achieved. That method has been used, for example, by Peters-Wendisch et al. (Microbiology 144, 915-927 (1998)) to exclude the pyc gene of C.

5 glutamicum by means of a deletion.

A deletion, insertion or a base substitution may thus be incorporated into the luxR gene.

In addition, it may be advantageous for the production of L-amino acids, particularly L-lysine, in addition to attenuating the luxR gene, to amplify, in particular to

- overexpress, one or more enzymes of the biosynthesis pathway in question, of glycolysis, of the anaplerotic pathway, of the pentose phosphate cycle or of amino acid export.
- 15 Accordingly, for example for the production of L-lysine, one or more genes selected from the group
  - the gene dapA coding for dihydrodipicolinate synthase (EP-B 0 197 335),
  - the gene eno coding for enolase (DE: 19947791.4),
- 20 the gene zwf coding for the zwf gene product (JP-A-09224661),
  - the gene pyc coding for pyruvate carboxylase (Peters-Wendisch et al. (Microbiology 144, 915 927 (1998)),
  - the gene lysE coding for lysine export (DE-A-195 48 222)
- 25 may at the same time be enhanced, in particular overexpressed.

In addition, it may be advantageous for the production of amino acids, particularly L-lysine, in addition to attenuation of the luxR gene, at the same time to attenuate 30 one or more genes selected from the group

- the gene pck coding for phosphoenol pyruvate carboxykinase (DE 199 50 409.1, DSM 13047),
- the gene pgi coding for glucose-6-phosphate isomerase (US 09/396,478, DSM 12969),
- 5 the gene poxB coding for pyruvate oxidase (DE:1995 1975.7, DSM 13114).

It may also be advantageous for the production of amino acids, particularly L-lysine, in addition to attenuating the luxR gene, to exclude undesired secondary reactions

10 (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The microorganisms produced according to the invention also form part of the invention and can be cultivated, for the purposes of the production of L-amino acids, in particular L-lysine, continuously or discontinuously in the batch, fed batch or repeated fed batch process. A summary of known cultivation methods are [sic] described in the textbook of

- 20 Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook of Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
- 25 The culture medium to be used must meet the requirements of the strains in question in a suitable manner. Descriptions of culture media for various microorganisms are to be found in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology
- 30 (Washington D.C., USA, 1981). There may be used as the carbon source sugars and carbohydrates, such as, for example, glucose, saccharose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as, for

example, soybean oil, sunflower oil, groundnut oil and coconut oil, fatty acids, such as, for example, palmitic acid, stearic acid and linoleic acid, alcohols, such as, for example, glycerol and ethanol, and organic acids, such as, for example, acetic acid. Those substances may be used individually or in the form of a mixture.

There may be used as the nitrogen source organic nitrogencontaining compounds, such as peptones, yeast extract, meat
extract, malt extract, corn steep liquor, soybean flour and
urea, or inorganic compounds, such as ammonium sulfate,
ammonium chloride, ammonium phosphate, ammonium carbonate
and ammonium nitrate. The nitrogen sources may be used
individually or in the form of a mixture.

There may be used as the phosphorus source phosphoric acid,

15 potassium dihydrogen phosphate or dipotassium hydrogen
 phosphate or the corresponding sodium-containing salts. The
 culture medium must also contain salts of metals, such as,
 for example, magnesium sulfate or iron sulfate, which are
 necessary for growth. Finally, essential growth substances,

20 such as amino acids and vitamins, may be used in addition
 to the above-mentioned substances. Suitable precursors may
 also be added to the culture medium. The mentioned
 substances may be added to the culture in the form of a
 single batch, or they may be fed in in a suitable manner

25 during the cultivation.

In order to control the pH value of the culture, basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acid compounds, such as phosphoric acid or sulfuric acid, are expediently used. In order to control the development of foam, anti-foams, such as, for example, fatty acid polyglycol esters, may be used. In order to maintain the stability of plasmids, suitable substances having a selective action, such as, for example, antibiotics, may be added to the medium. In order to maintain aerobic conditions, oxygen or gas mixtures

containing oxygen, such as, for example, air, are introduced into the culture. The temperature of the culture is normally from 20°C to 45°C and preferably from 25°C to 40°C. The culture is continued until the maximum amount of the desired product has formed. That aim is normally achieved within a period of from 10 hours to 160 hours.

Methods of determining L-amino acids are known from the prior art. The analysis may be carried out, for example, as described in Spackman *et al*. (Analytical Chemistry, 30,

10 (1958), 1190) by anion-exchange chromatography with subsequent ninhydrin derivatization, or it may be carried out by reversed phase HPLC, as described in Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

The following microorganisms were deposited at the Deutsche
15 Sammlung für Mikroorganismen und Zellkulturen (DSMZ,
Braunschweig, Germany) in accordance with the Budapest
Treaty:

- Escherichia coli strain TOP10F/pCR2.1luxRint as DSM 13619.
- 20 The process of the invention is used for the production of amino acids, in particular L-lysine, by fermentation.

The present invention is explained in greater detail below by means of Examples.

The isolation of plasmid DNA from Escherichia coli and all techniques for restriction, Klenow and alkaline phosphatase treatment were carried out according to Sambrook et al. (Molecular Cloning. A Laboratory Manual, 1989, Cold Spring Harbour Laboratory Press, Cold Spring Harbor, NY, USA). Methods for the transformation of Escherichia coli are also described in that handbook.

The composition of common nutrient media, such as LB or TY medium, will also be found in the handbook of Sambrook et al.

# Example 1

5 Preparation of a genomic cosmid gene library from C. glutamicum ATCC 13032

Chromosomal DNA from C. glutamicum ATCC 13032 was isolated as described in Tauch et al. (1995, Plasmid 33:168-179) and partially cleaved with the restriction enzyme Sau3AI

- 10 (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, Code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, Code no. 1758250). The DNA of cosmid
- 15 vector SuperCosl (Wahl et al. (1987), Proceedings of the National Academy of Sciences, USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, product description SuperCosl Cosmid Vektor Kit, Code no. 251301), was cleaved with the restriction enzyme XbaI (Amersham Pharmacia,
- 20 Freiburg, Germany, product description XbaI, Code no. 27-0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.

The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product

- description BamHI, Code no. 27-0868-04). The cosmid DNA so treated was mixed with the treated ATCC13032 DNA, and the batch was treated with T4-DNA ligase (Amersham Pharmacia, Freiburg, Germany, product description T4-DNA ligase, Code no. 27-0870-04). The ligation mixture was then packed in
- 30 phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, product description Gigapack II XL Packing Extract, Code no. 200217).

For infection of E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Res. 16:1563-1575), the cells were taken up in 10 mM MgSO<sub>4</sub> and mixed with an aliquot of the phage suspension. Infection and titration of the cosmid library 5 were carried out as described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) + 100 μg/ml ampicillin. After incubation overnight at 37°C, recombinant individual clones 10 were selected.

# Example 2

Isolation and sequencing of the luxR gene

The cosmid DNA of an individual colony was isolated using the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, 15 Hilden, Germany) according to the manufacturer's instructions, and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI R

product description Sau3AI, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim,

Germany, product description SAP, Product No. 1758250). After separation by gel electrophoresis, cosmid fragments having a size in the range from 1500 to 2000 bp were isolated using the QiaExII Gel Extraction Kit (Product No.

25 20021, Qiagen, Hilden, Germany).

The DNA of sequencing vector pZero-1, obtained from Invitrogen (Groningen, Netherlands, product description Zero Background Cloning Kit, Product No. K2500-01), was cleaved with the restriction enzyme BamHI (Amersham

Pharmacia, Freiburg, Germany, product description BamHI, Product No. 27-0868-04). Ligation of the cosmid fragments into the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture

being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). The ligation mixture was then electroporated into E. coli strain DH5αMCR (Grant, 1990, Proceedings of the National Academy of Sciences, U.S.A.,
5 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-347) and plated out on LB agar (Lennox, 1955, Virology, 1:190) with 50 μg/ml Zeocin.

Plasmid preparation of the recombinant clones was carried out using the Biorobot 9600 (Product No. 900200, Qiagen,

- 10 Hilden, Germany). Sequencing was effected by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academies of Sciences, U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR
- 15 dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. Separation by gel electrophoresis and analysis of the sequencing reaction was carried out in a "Rotiphorese NF Acrylamid/Bisacrylamid" gel (29:1) (Product No. A124.1,
- 20 Roth, Karlsruhe, Germany) using the "ABI Prism 377" sequencing device from PE Applied Biosystems (Weiterstadt, Germany).

The resulting crude sequence data were then processed using the Staden program package (1986, Nucleic Acids Research,

- 25 14:217-231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a coherent contig. The computer-assisted coding region analysis was prepared using the program XNIP (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analyses were carried out using the
- 30 "BLAST search program" (Altschul et al., 1997, Nucleic Acids Research, 25:33893402) against the non-redundant data bank of the "National Center for Biotechnology Information" (NCBI, Bethesda, MD, USA).

The resulting nucleotide sequence is shown in SEQ ID No. 1. 35 Analysis of the nucleotide sequence gave an open reading

frame of 639 bp, which was designated the luxR gene. The luxR gene codes for a polypeptide of 212 amino acids.

# Example 3

Preparation of an integration vector for integration 5 mutagenesis of the luxR gene

Chromosmal DNA was isolated from strain ATCC 13032 by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)). On the basis of the sequence of the luxR gene known from Example 2 for C. glutamicum, the following oligonucleotides were selected for the polymerase chain reaction:

luxRintA:

5'GGA ATC GAC GTC ATC TTG AT 3'

luxRintB:

15 5'GCA ACC AGC TTG AGA ACT TC 3'

The primers shown were synthesised by MWG Biotech (Ebersberg, Germany), and the PCR reaction was carried out according to the standard PCR method of Innis et al. (PCR protocols. A Guide to Methods and Applications, 1990,

20 Academic Press) using Pwo polymerase from Boehringer. With the aid of the polymerase chain reaction, an internal fragment of the luxR gene having a size of 353 bp was isolated and is shown in SEQ ID No. 3.

The amplified DNA fragment was ligated into vector pCR2.1-25 TOPO (Mead et al. (1991), Bio/Technology 9:657-663) using the TOPO TA Cloning Kit from Invitrogen Corporation (Carlsbad, CA, USA; Catalog Number K4500-01).

E. coli strain TOP10F was then transformed with the ligation batch (Hanahan, in: DNA cloning. A Practical

30 Approach. Vol. I, IRL-Press, Oxford, Washington DC, USA, 1985). The selection of plasmid-carrying cells was carried out by plating out the transformation batch on LB agar

(Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) which had been supplemented with 25 mg/l kanamycin. Plasmid DNA was isolated from a 5 transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and was tested by restriction with the restriction enzyme EcoRI and subsequent agarose gel electrophoresis (0.8%). The plasmid was named pCR2.1luxRint.

# 10 Example 4

Integration mutagenesis of the luxR gene in the lysine producer DSM 5715

Vector pCR2.1luxRint mentioned in Example 3 was electroporated in C. glutamicum DSM 5715 by the

- 15 electroporation method of Tauch et al. (FEMS Microbiological Letters, 123:343-347 (1994)). Strain DSM 5715 is an AEC-resistant lysine producer. Vector pCR2.1luxRint is unable to replicate independently in DSM 5715 and is retained in the cell only if it has integrated into the chromosome of
- 20 DSM 5715. The selection of clones with pCR2.lluxRint integrated into the chromosome was effected by plating out the electroporation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.)
- 25 which had been supplemented with 15 mg/l kanamycin.

In order to demonstrate the integration, the luxRint fragment was labelled by the method "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) using the Dig hybridization

30 kit from Boehringer. Chromosomal DNA of a potential integrant was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)) and cleaved with each of the restriction enzymes SalI, SacI and HindIII. The resulting fragments were separated by means of agarose gel

electrophoresis and hybridized at 68°C using the Dig hybridization kit from Boehringer. Plasmid pCR2.1luxRint mentioned in Example 3 had inserted into the chromosome of DSM 5715 within the chromosomal luxR gene. The strain was 5 designated DSM 5715::pCR2.1luxRint.

### Example 5

pH 7.4

Production of L-lysine

The C. glutamicum strain DSM 5715::pCR2.1luxRint obtained in Example 4 was cultivated in a nutrient medium suitable for the production of L-lysine, and the L-lysine content in the culture supernatant was determined.

To that end, the strain was first incubated for 24 hours at 33°C on agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/l). Starting from 15 that agar plate culture, a pre-culture was inoculated (10 ml of medium in 100 ml Erlenmeyer flasks). CgIII complete medium was used as the medium for the pre-culture.

#### Cg III medium

NaCl 2.5 g/l Bacto-peptone 10 g/l Bacto-yeast extract 10 g/l Glucose (autoclaved separately) 2% (w/v) The pH value was adjusted to

Kanamycin (25 mg/l) was added thereto. The pre-culture was 20 incubated for 24 hours at 33°C at 240 rpm on a shaker. A main culture was inoculated from that pre-culture, so that the initial OD (660 nm) of the main culture was 0.1 OD. MM medium was used for the main culture.

#### MM medium

CSL (corn steep liquor)	5 g/l
MOPS	20 g/l
Glucose (autoclaved separately)	50 g/l
Salts:	
$(NH_4)_2SO_4)$ [sic]	25 g/l
KH <sub>2</sub> PO <sub>4</sub>	0.1 g/l
$MgSO_4 * 7 H_2O$	1.0 g/l
$CaCl_2 * 2 H_2O$	10 mg/l
FeSO <sub>4</sub> * 7 H <sub>2</sub> O	10 mg/l
$MnSO_4 * H_2O$	5.0 mg/l
Biotin (sterilised by filtration)	0.3 mg/l
Thiamin * HCl (sterilised by filtration)	0.2 mg/l
Leucine (sterilised by filtration)	0.1 g/l
CaCO <sub>3</sub>	25 g/l

CSL, MOPS and the salt solution are adjusted to pH 7 with ammonia water and autoclaved. The sterile substrate and vitamin solutions are then added, as well as the dry 5 autoclaved  $CaCO_3$ .

Cultivation is carried out in a volume of 10 ml in a 100 ml Erlenmeyer flask with baffles. Kanamycin (25 mg/l) was added. Cultivation was carried out at  $33^{\circ}$ C and  $80^{\circ}$  humidity.

10 After 72 hours, the OD was determined at a measuring wavelength of 660 nm using a Biomek 1000 (Beckmann

Instruments GmbH, Munich). The amount of L-lysine that had formed was determined using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion-exchange chromatography and post-column derivatization with 5 ninhydrin detection.

The result of the test is shown in Table 1.

Table 1

Strain	OD(660)	Lysine HCl				
		g/l				
DSM 5715	7.5	13.01				
DSM 5715::pCR2.1luxRint	8.8	15.41				

```
SEQUENCE PROTOCOL
    <110> Degussa-Hüls AG
  5 <120> Novel nucleotide sequences coding for the luxR gene
    <130> 000177 BT
     <140>
 10 <141>
    <160> 3
    <170> PatentIn Ver. 2.1
15
    <210> 1
    <211> 1052
    <212> DNA
    <213> Corynebacterium glutamicum
20
    <220>
    <221> CDS
    <222> (214)..(849)
    <223> luxR gene
    <400> 1
    tgcagcattg ccggtggagc caccagaggg gtttgtcggg gcgccggttt tggcagattc 60
    ggactcaagt gctacaggcg aggttgaact aagttctcca actgacgatg agtaaggcta 120
30
    gactaaagta cgattcatct gctcatcgat actcttgaag gcgcattttc attcgaaacg 180
    aagtgcgcca ttgggaagga cctagttcaa aca atg att cgc gtg ctg ctt gct
                                          Met Ile Arg Val Leu Leu Ala
35
    gat gac cac gaa atc gtg agg ctc gga ctc cga gct gtg ctg gaa agc
                                                                       282
    Āsp Āsp His Ğlu Ile Val Arg Leu Ğly Leu Arg Āla Val Leu Ğlu Ser
    gcc gag gac att gaa gtg gtg ggc gaa gtc tcc acc gcc gaa ggt gcg
    Ála Glú Ásp Ile Glu Val Val Gly Glu Val Ser Thr Ála Glu Gly Ála
         25
   gtg cag gca gcc caa gaa ggc gga atc gac gtc atc ttg atg gac ctc
    Val Gln Ála Ála Gln Glu Gly Gly Ile Ásp Val Ile Leu Met Ásp Leu
    cga ttc ggc ccc ggc gtc caa gga acc cag gtt tcc aca ggc gca gac
50 Arg Phe Gly Pro Gly Val Gln Gly Thr Gln Val Ser Thr Gly Ala Asp
                                                                       426
   gcc acc gca gcc atc aag cga aac atc gat aac ccg cca aaa gtc ctg
                                                                       474
   Ala Thr Ala Ala Ile Lys Arg Asn Ile Asp Asn Pro Pro Lys Val Leu
55
                                     80
   gtc gtg acc aac tac gac acc gac aca gac atc ctc ggc gca atc gaa
                                                                       522
   Val Val Thr Asn Tyr Ásp Thr Ásp Thr Ásp Ile Leu Gly Ála Ile Glu
60
   gee gge gea etg gge tae etg ete aaa gae gee eea eeg age gaa ete
   Ala Gly Ala Leu Gly Tyr Leu Leu Lys Asp Ala Pro Pro Ser Glu Leu
                                                                       570
       105
                            110
                                                115
```

	5	120					12		u 11 <u>1</u>	.a G.	ru G	1 A	.sp :	er '	Thr	Let	ı Ş	er	Pro 135	618
_						14	ŏ	g ato u Mei	- 111	T VI	1.9 V.	45	rg 1	nr i	Pro	Lys	T)	nr 50	Ser	666
1					155	5		g gaa u Glu		16	50	уз ц	eu v	aı A	<i>1</i> та	165	GJ	-У	Ser	714
1	5	tcc Ser	aac Asn	cgc Arg 170	gac Asp	att Ile	t gge ∋ Gl	c cgt y Arg	ate J Ile 17	с пе	c tt	ic ci	tc t eu S	er G	gaa Slu .80	gcc Ala	· ac Th	g ir	gtg Val	762
2	0	aaa Lys	tcc Ser 185	cac His	ctc Leu	gto Val	g cad L His	c ato s Ile 190	. T A -	c ga r As	c aa p Ly	ig ct 's Le	eu G	gc g ly V 95	tg al	cgg Arg	t c Se	a o	cgt Arg	810
25	- 2	hr 200	tcc Ser	gct Ala	gtc Val	gca Ala	a gcd Ala 205	gca Ala	cgt	t ga g Gl	g ca u Gl	g gg n Gl 21	.у ь	tg c eu L	tg eu	tago	egg	ggç	gt	859
	t	gct	gcaa	agg d	cttt	aggt	at c	cgcg	ccgc	ag g	ttgg	ccta	c go	ggag	cat	cc d	cga	ggc	ttta	919
	ç	jcag.	gggd	cac o	gggc.	tctg	gc t	tggg	ctga	g to	cagg	ggcg	c gg	jcca	atgo	ct t	tc	cga	Gaca	 979
. 30	) t	gtc	tcca	ecg ç	gctt	tatt	ta g	tttt	tcaa	ıg aa	agtt	tgac	g aa	agato	acat	ta o	ato	-c+	cttc	1039
	g	ġgc	cagt	ct g	jaa								-	. برد	J - J ·		,			1059
35	< <	210: 211: 212:	> 21 > PR	T																1032
				ryne	bact	eri	um g	lutan	nicu	m										
40	< ·	400> et I 1	· 2 :le .	Arg	Val	Leu 5	Leu	Ala	Asp	Asp	His	Glu	ı Ile	e Va	l A	rg ]	Leu 15	G]	Ly	•
45								Ser		2,5						30	Sly			
50								Äla	- 0					4:	5		•			
								Leu 55					60	,						
55								Asp .				15						- 80	0	
								Leu '			90						95			
60								Glu <i>I</i>		105					11	0				
	Ası	Al	a P	ro P	ro s	Ser (	31,,	Leu I		71 -										

Gly Asp Ser Thr Leu Ser Pro Met Val Ala Asn Arg Leu Met Thr Arg 5 Val Arg Thr Pro Lys Thr Ser Leu Thr Pro Arg Glu Leu Glu Val Leu 155 Lys Leu Val Ala Gly Gly Ser Ser Asn Arg Asp Ile Gly Arg Ile Leu 170 10 Phe Leu Ser Glu Ala Thr Val Lys Ser His Leu Val His Ile Tyr Asp 185 Lys Leu Gly Val Arg Ser Arg Thr Ser Ala Val Ala Ala Arg Glu 200 205 Gln Gly Leu Leu 210 20 <210> 3 <211> 353 <212> DNA 25 <213> Corynebacterium glutamicum <220> <223> luxRint 30 <400> 3 ggaatcgacg tcatcttgat ggacctccga ttcggccccg gcgtccaagg aacccaggtt 60 tecacaggeg cagaegecae egeagecate aagegaaaca tegataaeee gecaaaagte 120 ctggtcgtga ccaactacga caccgacaca gacatcctcg gcgcaatcga agccggcgca 180 ctgggctacc tgctcaaaga cgccccaccg agcgaactcc tggcagcagt acgatccgca 240 gcagaaggtg actccacact gtcacccatg gttgcgaacc gcctgatgac tcgcgtgcgc 300 acccccaaaa cctcactcac cccacgtgaa ctggaagttc tcaagctggt tgc 353

The following figures are attached: Figure 1: Map of plasmid pCR2.1luxRint.

The abbreviations and names used have the following meanings.

KmR:

kanamycin resistance gene

EcoRI:

cleavage site of the restriction enzyme

EcoRI

luxRint:

internal fragment of the luxR gene

ColE1 ori:

origin of replication of plasmid ColE1

5

## Patent claims

10

- An isolated polynucleotide from coryneform bacteria, containing a polynucleotide sequence coding for the luxR gene, selected from the group
- a) polynucleotide that is at least 70% identical with a polynucleotide that codes for a polypeptide containing the amino acid sequence of SEQ ID No. 2,
  - b) polynucleotide that codes for a polypeptide containing an amino acid sequence that is at least 70% identical with the amino acid sequence of SEQ ID No. 2,
    - c) polynucleotide that is complementary to the polynucleotide of a) or b), and
- d) polynucleotide containing at least 15 consecutive nucleotides of the polynucleotide sequence of a), b) or c),

the polypeptide preferably exhibiting the activity of the transcription activator LuxR.


- A polynucleotide as claimed in claim 1, wherein the
   polynucleotide is a DNA, preferably a recombinant DNA,
   that is replicatable in coryneform bacteria.
  - A polynucleotide as claimed in claim 1, wherein the polynucleotide is an RNA.
  - 4. A replicatable DNA as claimed in claim 2, containing
- 25 (i) the nucleotide sequence shown in SEQ ID No. 1, or
  - (ii) at least one sequence that corresponds to sequence (i) within the region of the degeneracy of the genetic code, or

5

15

25

- (iii) at least one sequence that hybridizes with the sequences that are complementary to sequence (i) or (ii), and optionally
- (iv) sense mutations in (i) that are neutral in terms of function.
- A coryneform bacteria in which the luxR gene is attenuated, preferably excluded.
- 7. A process for the preparation of L-amino acids, in particular L-lysine, which process comprises carrying out the following steps:
  - a) fermenting the bacteria that produce the desired L-amino acid, in which bacteria at least the luxR gene is attenuated,
  - b) concentrating the desired product in the medium or in the cells of the bacteria, and
    - c) isolating the L-amino acid.
- A process as claimed in claim 7, wherein there are used bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced.
  - 9. A process as claimed in claim 7, wherein there are used bacteria in which at least some of the metabolic pathways that reduce formation of the desired L-amino acid are excluded.
  - 10. A process as claimed in claim 7, wherein expression of the polynucleotide(s) coding for the luxR gene is diminished, in particular excluded.
- 11. A process as claimed in claim 7, wherein the 30 regulatory properties of the polypeptide for which the polynucleotide luxR codes are diminished.



- 12. A process as claimed in claim 7, wherein for the production of L-amino acids, particularly L-lysine, bacteria are fermented in which at the same time one or more genes selected from the group
- 5 12.1 the gene dapA coding for dihydrodipicolinate synthase,
  - 12.2 the gene eno coding for enolase,
  - 12.3 the gene zwf coding for the zwf gene product,
  - 12.4 the gene pyc coding for pyruvate carboxylase,
- 10 12.5 the gene lysE coding for lysine export, are enhanced, in particular overexpressed.
  - 13. A process as claimed in claim 7, wherein at the same time one or more genes selected from the group:
- 13.1 the gene pck coding for phosphoenol pyruvate carboxykinase,
  - 13.2 the gene pgi coding for glucose-6-phosphate isomerase,
  - 13.3 the gene poxB coding for pyruvate oxidase are attenuated.
- 20 14. A process as claimed in one or more of the preceding claims, wherein microorganisms of the species Corynebacterium glutamicum are used.
- 15. A method of finding RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes, that code for the transcription activator LuxR or have a high degree of similarity with the sequence of the luxR gene, which method comprises using the polynucleotide sequences as claimed in claims 1 to 4 as hybridization probes.

000177 BT

# Novel nucleotide sequences coding for the luxR gene

#### Abstract

Isolated polynucleotide containing a polynucleotide sequence selected from the group

- 5 a) polynucleotide that is at least 70% identical with a polynucleotide that codes for a polypeptide containing the amino acid sequence of SEQ ID No. 2,
- b) polynucleotide that codes for a polypeptide containing an amino acid sequence that is at least 70% identical
   with the amino acid sequence of SEQ ID No. 2,
  - c) polynucleotide that is complementary to the polynucleotide of a) or b), and
- d) polynucleotide containing at least 15 consecutive nucleotides of the polynucleotide sequence of a), b) or c),

and a process for the production of L-amino acids by fermentation using coryneform bacteria in which at least the luxR gene is present in attenuated form, and the use of the polynucleotide sequences as hybridization probes.

Figure 1: Plasmid map of pCR2.1luxRint

